Uzbekistan’s Pharmaceutical Market Strengthens Its Position Among Eurasian Leaders as STADA Expands Presence in Key Segments

Tashkent, Uzbekistan (UzDaily.com) — On 20 January, STADA summarized the results of 2025 in Tashkent and highlighted key trends in the development of Uzbekistan’s pharmaceutical market.

From December 2024 to November 2025, the country’s pharmaceutical market confirmed its status as one of the leading markets in Eurasia, while remaining among the most dynamic in terms of growth.

Uzbekistan, alongside Kazakhstan, forms the “core” of regional pharmaceutical demand. Despite a significantly smaller share of government procurement, the Uzbek market has approached Kazakhstan in terms of total volume, underscoring the resilience of the retail segment and the strong role of consumer demand.

According to IQVIA data (MAT’11’25), Uzbekistan’s pharmaceutical market demonstrated solid growth both in value and in physical terms. Sales in the national currency reached 25,984 billion soums, up 28% compared with the same period last year (MAT’11’24 — 20,299 billion soums). In physical terms, the market grew to 0.86 billion units compared with 0.81 billion units a year earlier (+6%). When converted into foreign currencies, growth amounted to +24% in US dollars and +22% in euros, while growth in standard units (SU) reached +2%.

Within the pharmaceutical demand structure in Eurasian countries, including Uzbekistan, the retail segment dominates, with prescription drugs (Rx) accounting for approximately 60–70% of sales in value terms. This model emphasizes the need for a broad and balanced portfolio, predictable drug supply, and clear patient access pathways.

Over the period MAT’11’25, STADA strengthened its position among the leading players in the over-the-counter (OTC) segment, achieving an 8.8% market share in value terms.

Company sales in the OTC segment grew by 60% compared with MAT’11’24, reflecting strong demand in key categories. Major contributors to growth included magnesium with vitamin B6 formulations and digestive health products, which remain primary drivers in the OTC segment.

STADA’s key priority in Uzbekistan is improving the accessibility and convenience of therapy for patients and healthcare professionals. The company consistently develops its portfolio across three main areas: OTC solutions for everyday health, generics, and specialized prescription drugs.

As part of this strategy, special attention is given to the development of biologics and expanding patient access to modern therapies.

“In 2024, STADA became a pioneer in this area in Uzbekistan by introducing the country’s first ophthalmology biosimilar. In 2025, we continued expanding the portfolio with a biosimilar in oncology. The drug is used in the treatment of colorectal cancer, breast cancer, lung cancer, renal cell carcinoma, ovarian cancer, and cervical cancer — areas where quality and stable drug supply are especially critical. It broadens therapeutic options for patients and provides doctors with additional treatment choices,” said Bakhtiyar Khadzhimuhamedov, Head of the “Uzbekistan + Kyrgyzstan” subcluster.

Alongside the development of specialized therapies, the company strengthened its cardiology portfolio in 2025 by introducing a drug for the treatment of arterial hypertension with cardioselective and vasodilatory properties, also applicable in angina and arrhythmias. In the OTC segment, STADA launched an updated line of digestive and immune health products for adults, focusing on convenience of use and improved adherence to therapy.

STADA plans to continue expanding its presence in the Uzbek market, strengthening collaboration with the professional medical community and improving access to high-quality, effective, and modern medicines for the country’s population.